Advertisement

Annals of Surgical Oncology

, Volume 11, Supplement 3, pp 147S–151S | Cite as

Sentinel node biopsy for melanoma: Where have we been and where are we going?

  • John F. Thompson
  • Jonathan R. Stretch
  • Roger F. Uren
  • Vivian S. Ka
  • Richard A. Scolyer
Article

Abstract

The sentinel node (SN) concept is not new, but its potential surgical application was not fully appreciated until the landmark report by Morton and Cochran et al. in 1992. It has since been confirmed that SN status in melanoma patients accurately reflects the status of the entire regional node field, and is a critically important prognostic indicator. However, randomized trials have yet to determine whether the SN biopsy technique is of any therapeutic value. With extended follow-up times, false-negative SN rates of up to 15% are being reported and presumably represent failures of nuclear medicine and/or surgery and/or histopathology. Innovative methods of increasing the accuracy of SN identification and of checking this retrospectively are being assessed. The next great challenge is to develop methods of SN assessment that are noninvasive yet are even more accurate than present methods. Techniques such as in vivo proton magnetic resonance spectroscopy hold great promise and suggest that this goal might be achievable.

Key Words

History Lymphatic mapping Melanoma Sentinel node 

References

  1. 1.
    Braithwaite LR. The flow of lymph from the ileocaecal angle, and its possible bearing on the cause of duodenal and gastric ulcer.Br J Surg 1923;11:7–26.Google Scholar
  2. 2.
    Gould EA, Winship T, Philbin PH, Kerr HH. Observations on a “sentinel node” in cancer of the parotid.Cancer 1960;13:77–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Sayegh E, Brooks T, Sacher E, Busch F. Lymphangiography of the retroperitoneal lymph nodes through the inguinal route.J Urol 1966;95:102–7.PubMedGoogle Scholar
  4. 4.
    Cabanas RM. An approach for the treatment of penile carcinoma.Cancer 1977;39:456–66.PubMedCrossRefGoogle Scholar
  5. 5.
    Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma.Arch Surg 1992;127:392–9.PubMedGoogle Scholar
  6. 6.
    Reintgen D, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases.Ann Surg 1994;220:759–67.PubMedCrossRefGoogle Scholar
  7. 7.
    Thompson JF, McCarthy WH, Bosch CM, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes.Melanoma Res 1995;5:255–60.PubMedGoogle Scholar
  8. 8.
    Essner R, Stern S, Bostick P, Morton DL. Results of lymphatic mapping in melanoma. In: Nieweg OE, Essner R, Reintgen D, Thompson JF, eds.Lymphatic Mapping and Probe Applications in Oncology, New York: Marcel Dekker, 2000:101–24.Google Scholar
  9. 9.
    Thompson JF, Niewind P, Uren RF, et al. Single-dose isotope injection for both preoperative lymphoscintigraphy and intraoperative sentinel lymph node identification in melanoma patients.Melanoma Res 1997;7:500–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Uren RF, Thompson JF, Howman-Giles R.Lymphatic Drainage of the Skin and Breast: Locating the Sentinel Nodes. Amsterdam: Harwood Academic Publishers, 1999.Google Scholar
  11. 11.
    Thompson JF, Uren RF, Shaw HM, et al. Location of sentinel lymph nodes in patients with cutaneous melanoma: new insights into lymphatic anatomy.J Am Coll Surg 1999;189:195–204.PubMedCrossRefGoogle Scholar
  12. 12.
    de Wilt JHW, Thompson JF, Uren RF, et al. Correlation between preoperative lymphoscintigraphy and metastatic nodal disease sites in 362 patients with cutaneous melanomas of the head and neck.Ann Surg (in press).Google Scholar
  13. 13.
    Thompson JF, Uren RF. What is a ‘sentinel’ lymph node?Eur J Surg Oncol 2000;26:103–4.PubMedCrossRefGoogle Scholar
  14. 14.
    Haigh PI, Lucci A, Turner RR, et al. Carbon dye histologically confirms the identity of sentinel lymph nodes in cutaneous melanoma.Cancer 2001;92:535–41.PubMedCrossRefGoogle Scholar
  15. 15.
    Dawson M, Doble P, Beavis A, et al. Antimony by ICP-MS as a marker for sentinel lymph nodes in melanoma patients.Analyst 2003;128:217–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Scolyer RA, Thompson JF, Li LX, et al. Failure to remove “true” sentinel nodes can cause failure of the sentinel node biopsy technique. Antimony quantitation in false negative sentinel nodes from melanoma patients.Ann Surg Oncol (in press).Google Scholar
  17. 17.
    Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial.Ann Surg 1999;230:453–63; discussion, 463–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Bonenkamp JJ, Logan DR, Suemnig AA, Thompson JF. The cost of sentinel node biopsy for melanoma.Melanoma Res 2001; 11(Suppl 1):S107.Google Scholar
  19. 19.
    Lean CL, Bourne R, Thompson JF, et al. Rapid detection of metastatic melanoma in lymph nodes using proton magnetic resonance spectroscopy of fine needle aspiration biopsy specimens.Melanoma Res 2003;13:259–61.PubMedCrossRefGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2004

Authors and Affiliations

  • John F. Thompson
    • 1
    • 2
    • 4
  • Jonathan R. Stretch
    • 1
    • 2
    • 4
  • Roger F. Uren
    • 1
    • 2
    • 5
  • Vivian S. Ka
    • 1
    • 2
  • Richard A. Scolyer
    • 1
    • 2
    • 3
  1. 1.Sydney Melanoma UnitRoyal Prince Alfred HospitalCamperdownAustralia
  2. 2.Melanoma and Skin Cancer Research InstituteRoyal Prince Alfred HospitalCamperdownAustralia
  3. 3.Department of Anatomical PathologyRoyal Prince Alfred HospitalCamperdownAustralia
  4. 4.Department of SurgeryUniversity of SydneySydneyAustralia
  5. 5.Department of MedicineUniversity of SydneySydneyAustralia

Personalised recommendations